Pharma channel feed – Endpoints News

Pharma channel feed

After Tesaro buy, GSK wades deeper into cancer unveiling big immunotherapy deal with Germany's Merck

7 years ago

As Herceptin biosimilars eat into Roche sales, Swiss drugmaker makes case for expanded Kadcyla use

7 years ago

In a field littered with failures, positive data prompt speedy US, EU review of AstraZeneca's long-acting RSV drug

7 years ago

Shakeup at the top of FDA’s biosimilars division as Leah Christl departs for Amgen

7 years ago

Baeuerle-backed Cullinan grows its pipeline of portfolio plays, adopts a new cancer drug with eye to clinical development

7 years ago

Evolus celebrates greenlight for Botox rival while Allergan counterattacks with a complaint of stolen trade secrets

7 years ago

Alkermes shares take another hit as the FDA shakes its head — again — on a weak case for '5461

7 years ago

MPs threaten to hijack Vertex’s IP for its cystic fibrosis drugs in a long-running standoff over price

7 years ago

Novo bets on swift FDA review for oral diabetes drug semaglutide

7 years ago

Trump administration proposes new rules that strip away many of the rebate deals between pharma and PBMs, pushing discounts to consumers

7 years ago

Alexion lines up a $60M option to buy Fortress-incubated biotech focused on a lucrative rare blood disease

7 years ago

J&J snags rights to a gene therapy portfolio from little MeiraGTx, a spinoff from Sam Waksal’s Kadmon

7 years ago

FDA blesses Merck’s PhIII effort to topple a mega-blockbuster — but there’s also a little biotech in this game

7 years ago

After a years-long reprieve, GSK is about to see Mylan’s generic carve into its mega-blockbuster Advair franchise

7 years ago

Voyager bags a 'transformational' $1.8B gene therapy pact with Neurocrine

7 years ago

Gottlieb lays out real world evidence priorities for 2019 with an eye on digital tools

7 years ago

Trevena forges plan to take once-rejected opioid across finish line, after 'productive' FDA meeting

7 years ago

The next 5 years: Higher R&D productivity is here to stay, emerging biotechs and new tech will have a big impact. But what about pricing?

7 years ago

EMA says symbolic goodbye to London HQ as it sets up shop in Amsterdam

7 years ago

Imbruvica regimen wins FDA approval as first non-chemotherapy treatment for untreated patients with common form of leukemia

7 years ago

Zai Lab nabs speedy China regulatory review for PARP drug Zejula

7 years ago

Scoop: GSK’s venture team at SR One in talks to spin off from its big pharma founder, now under new R&D management

7 years ago

Novartis sounds alarm on unsustainable drug supply chain if no-deal Brexit becomes reality

7 years ago

In another setback for Eli Lilly, FDA follows EMA in calling for a halt to new Lartruvo prescriptions

7 years ago

First page Previous page 277 278 279280281 282 283 Next page Last page